Aims Although drug-eluting stents have assumed a dominant role in interventional cardiology, concern has been raised about the potential for long-term adverse outcomes, including death. The aim of the present study was to compare the incidence and cause of death between patients who received sirolimus-eluting or bare metal stents. Methods and results An integrated analysis was performed on 1748 patients enrolled in four prospective double-blind trials that randomly assigned patients to receive either a sirolimus-eluting or a bare metal stent for treatment of a single de novo coronary stenosis. During a mean follow-up of 2.6 + 0.6 years, 64 patients (3.7%) died. Total mortality was 3.2% among 870 bare metal stent patients and 4.1% among 878 sirolimus-eluting stent patients (P ¼ 0.37); there was no difference in cardiac mortality (1.4 vs. 1.3%; P ¼ 0.55) or causes of death between these two groups. The predominant cause of death was noncardiac. Cardiac death was most frequently assigned owing to unwitnessed death. Death due to acute myocardial infarction, congestive heart failure, and stent thrombosis occurred infrequently. Conclusion At a mean follow-up of 2.6 years in percutaneous coronary intervention patients, the predominant cause of death was non-cardiac. There was no significant difference in either the frequency or the cause of death with implantation of either sirolimus-eluting or bare metal stents.
Introduction
The use of drug-eluting coronary stents has dramatically changed the field of interventional cardiology and has become the dominant percutaneous interventional strategy based on the results of randomized clinical trials and registries. Two stents, the sirolimus-eluting CYPHER (Cordis Corp., Miami, FL, USA) and the paclitaxel-eluting TAXUS (Boston Scientific Corp., Natick, MA, USA), have been shown to decrease both angiographic and clinical restenosis rates. [1] [2] [3] [4] [5] [6] [7] [8] This improvement in clinical and angiographic restenosis has resulted in the use of these stents in 80-90% of all percutaneous coronary interventions. Concern has been raised, however, about the potential for delayed subacute and late thrombosis and death. [9] [10] [11] [12] [13] [14] In registry experiences, the risk of thrombosis extends for a longer period with drug-eluting stents than with bare metal stents. Iakovou et al. 9 reported on 29 patients with stent thrombosis at follow-up of 9 months; these 29 patients represented 1.3% of the 2229 consecutive registry patients who received drug-eluting stents between 2002 and 2004. To assess late death, longer-term follow-up is required. The present report focuses on late death in four randomized multicentre clinical trials of sirolimus-eluting stents vs. bare metal stents.
Methods
The basis of the present analysis is four prospective, randomized, double-blind, institutional review board-approved clinical trials ( Table 1) : RAVEL 1,2 [randomized double-blind study with the sirolimus-eluting Bx VELOCITY (Cordis Corp.) balloon-expandable stent in the treatment of patients with de novo coronary artery lesions], SIRIUS 3, 4 (sirolimus-eluting stents in de novo native coronary artery lesions), E-SIRIUS 5 (European study of sirolimus-eluting stents in de novo native coronary artery lesions), and C-SIRIUS 6 (Canadian study of sirolimus-eluting stents in de novo native coronary artery lesions). Each study included patients with a single de novo lesion in native coronary arteries who were randomly assigned to receive implanted sirolimus-eluting Bx VELOCITY stents (SESs) or Bx VELOCITY bare metal stents (BMSs). Neither the investigator nor the patient knew which stents were implanted because they are visually identical and were packed in identical containers.
The coordination and data management of the three SIRIUS studies were performed by the Harvard Clinical Research Institute (Boston, MA, USA), and the data of the RAVEL study were managed by Cardialysis BV (Rotterdam, the Netherlands).
The 8-month angiographic follow-up data of the three SIRIUS studies were assessed at the Brigham and Women's Angiographic Core Laboratory (Boston, MA, USA), whereas the 6-month quantitative coronary angiographic follow-up data of RAVEL were processed by the Cardialysis BV core laboratory. All patients will be followed-up clinically for 5 years. Major clinical events were adjudicated by an independent clinical events committee.
The design of each trial is shown in Table 1 . In addition to the primary endpoints for each trial, clinical endpoints included death, myocardial infarction, repeat percutaneous coronary intervention, coronary artery bypass surgery, and stent thrombosis. There was variability in the antiplatelet therapy regimens used after hospital discharge.
In each of these trials, follow-up clinical data were available for at least 2 years. Information on the circumstances of the deaths was obtained from each of the sites and narratives were developed. These narratives were reviewed by the clinical events committee for the trials and also by the principal author of this manuscript (D.R.H.). The cause of death was then classified as 'cardiac' or 'noncardiac'. If the cause of death was unknown, it was attributed to cardiac causes. Cardiac death was further subdivided into death related to acute myocardial infarction, congestive heart failure, stent thrombosis, or a revascularization procedure. Each documented non-cardiac cause of death was also tabulated. The timing of death relative to the index procedure was tabulated. In addition, the results of intervening follow-up angiography were evaluated for the presence of either in-stent or in-lesion restenosis (defined as angiographic restenosis .50%) as well as for the occurrence of either target vessel or target lesion revascularization. This integrated analysis was not pre-specified in the protocols for these trials.
Statistical analysis
All studies used intention-to-treat analyses. Entire groups of patients who died were compared with patients who survived, and patients who received the SES were compared with patients who received the BMS.
The two-tailed t-test was used to compare the treatment difference, the homogeneity of the variance was tested, and the t-test P-value and the 95% confidence interval of the mean difference were presented accordingly, in addition to the summaries of mean and standard deviation of each treatment group. For the categorical variables, the percentage difference, the 95% confidence interval, and the two-sided Fisher exact test P-value were reported. The Kaplan-Meier method was used to evaluate survival for patients with SESs and for patients with BMSs according to the cause of death, with differences between event-free survival curves assessed by the log-rank test. A conventional statistical significance level of 5% (P , 0.05) was used. All statistical analyses were performed using SAS Version 8.2 (SAS Institute, Cary, NC, USA).
To explore the association between time-to-death and patient demographics and lesion characteristics, a univariable analysis was performed first by using the Cox proportional hazards regression model with time-to-death as the dependent variable and each of the patient demographic and lesion characteristic variables as covariates. The covariate coefficient, standard error, x 2 statistic, hazard ratio, and 95% confidence interval of each covariate were summarized. A multivariable analysis was then performed with the Cox proportional hazards regression model. A stepwise selection procedure was used with an entry criterion of 0.20 and a stay criterion of 0.10. The covariate coefficient, standard error, x 2 statistic, hazard ratio, and 95% confidence interval, using selected covariates that were included in the multivariable Cox regression model, were presented.
Results
A total of 1748 patients from these four trials were included in this analysis: 878 received the SES and 870 received the BMS. Follow-up clinical data compliance over 2 years averaged 96.4%. The mean follow-up was 2.6 + 0.6 years. Poolability of these data is supported by the similar trial designs and the comparable patient demographics, lesion ACT, activated clotting time; bid, twice daily; BMS, bare metal stent; DES, drug-eluting stent; qd, every day; TVF, target vessel failure.
characteristics, and major adverse cardiac events across the four trials within both the sirolimus-eluting and the control groups. [1] [2] [3] [4] [5] [6] There were few significant differences in baseline clinical characteristics between patients who died and those who survived during 2.6 + 0.6 years of follow-up ( Table 2) . In the SES patients, these clinical characteristics included mean age at the index procedure, 69.9 + 9.5 vs. 61.5 + 11.1 years (P , 0.001); history of congestive heart failure, 13.9 vs. 5.7% (P ¼ 0.01); and less frequent singlevessel disease, 44.4 vs. 62.1% (P ¼ 0.04). In the BMS patients, the only significant difference was age: 66.6 + 9.5 years among patients who died vs. 61.8 + 10.7 years among patients who survived (P ¼ 0.02). No other significantly different baseline characteristics were found.
There were few differences in baseline angiographic findings between patients who died and those who survived during 2.6 + 0.6 years of follow-up. In the SES patients, LAD location predominated (in 41.7% of the patients who died and in 46.8% of the patients who survived; P ¼ 0.61), and typically the stenosis was in the mid-portion of the vessel. Patients who died had a higher proportion of shorter lesions (,10 mm) treated than those who survived (44.4 vs. 26.8%; P ¼ 0.03). In the BMS patients, the only significant differences were that patients who died, compared with patients who survived, had a higher proportion of ulcerated lesions (17.4 vs. 5.7%; P ¼ 0.046) and aneurysm lesions (17.4 vs. 4.0%; P ¼ 0.02).
There were few differences in procedural characteristics between patients who died and survivors ( Table 3 ). In the SES group, there were no significant differences. In the control BMS group, two variables were significantly different: patients who died were less likely to have received a glycoprotein IIb/IIIa agent (21.4 vs. 44.1%; P ¼ 0.02) and were less likely to have received a 3.5-mm stent (7.7 vs. 26.3%; P ¼ 0.01), although there was no significant difference in baseline minimal luminal diameter (MLD).
Eight-month quantitative angiographic follow-up data were available for 28 patients who died and for 1082 patients who survived (including both SES patients and BMS patients). Overall, in the combined group of SES and BMS patients, there was no difference in binary restenosis (28.6% for patients who died vs. 23.7% for patients who survived; P ¼ 0.51). There was also no significant difference in the in-stent MLD or the stenosis diameter between those who died and the survivors. There was, however, a difference in MLD at the proximal edge; in patients who died, MLD was 1.98 + 0.80 mm and in survivors, 2.42 + 0.68 mm (P ¼ 0.001). The late loss (i.e. the difference between MLD immediately after the procedure and MLD at follow-up) at the location was correspondingly greater in patients who died than in survivors (0.52 + 0.71 vs. 0.24 + 0.55 mm; P ¼ 0.01).
During a mean follow-up of 31.6 + 7.3 months, total mortality as well as the cause of death (i.e. cardiac vs. noncardiac) varied among the trials ( Table 4) . There was no difference in cardiac mortality between the two groups, with deaths occurring in 14 BMS and 11 SES patients (P ¼ 0.55). Total mortality was numerically lower in the BMS patients (28/870; 3.2%) than in the SES patients (36/ 878; 4.1%), but the difference was not statistically significant (P ¼ 0.37). The numerical difference in total mortality was the result of an imbalance in non-cardiac deaths. Kaplan-Meier curves for all-cause mortality and cardiac mortality are shown in Figure 1 . Cause of death was determined from case report forms and written narratives. Causes of cardiac and non-cardiac death are presented in Table 5 . Approximately 60% of deaths (39/64) were from a non-cardiac cause. Nine causes of non-cardiac death were identified, with neurological disease (predominantly stroke), cancer, and sepsis being the most frequent aetiologies of non-cardiac death. A plot of time vs. the cumulative frequency of death ( Figure 1C) indicates that the non-cardiac deaths for the BMS and SES groups overlap until 180 days, when they separate and are subsequently higher (numerically but not statistically) for the SES group. Examination of death rates in each trial used in this integrated analysis demonstrates that this numerical excess of non-cardiac deaths is contributed by two smaller trials (RAVEL and C-SIRIUS) but not by the much larger SIRIUS trial.
A specific cardiac cause of death was attributed in 40% of deaths (25/64). The most common cause of cardiac death was unwitnessed death or death of unknown cause, denoted as 'Unknown' in Table 5 (12 of 14 in the BMS group and six of 11 in the SES group). Acute myocardial infarction and congestive heart failure were each identified as additional causes of cardiac death in two patients in each group. One death in the BMS group and three deaths in the SES group occurred with revascularization procedures.
Protocol-defined stent thrombosis was identified in 14 patients, five patients treated with BMS and nine patients treated with SES (P ¼ 0.42) (Figure 2) . Although death occurred in one BMS and three SES patients (P ¼ 0.62) who experienced a stent thrombosis, only one death in each group was temporally related to the thrombotic event [i.e. the BMS patient died on day 30, the same day as the thrombosis, and the SES patients died on days 542 (three days after the thrombotic event), 802 (29 days after the With use of the multiple Cox proportional hazards model, multivariable predictor analysis of all deaths identified that, after adjusting for other predictors, age, history of congestive heart failure, renal insufficiency, and smoking were associated with a greater hazard of death, whereas administration of a glycoprotein IIb/IIIa inhibitor and a history of percutaneous coronary intervention were associated with a lower hazard of death ( Table 6 ). The type of stent (bare metal or sirolimus-eluting) was not identified in this model.
Discussion
This study provides an important perspective on the cause of death for patients with cardiovascular disease. Although the main cause of death in Western civilizations is cardiovascular disease, this analysis indicates that the main cause of death in patients with cardiovascular disease entered into pivotal clinical trials and followed for a mean of 2.6 years is, in fact, non-cardiac. In patients in whom the cause of death was unknown, it was attributed to a cardiac cause. Despite a cardiac cause of death being attributed in 28% of cases owing to insufficient detail surrounding the patients' deaths, 60% of patients in this pooled analysis of four clinical studies had a documented non-cardiac cause of death. Whether this means that contemporary coronary intervention might, in fact, reduce the risk of cardiac death is uncertain but provocative. The role of revascularization therapy in the prevention of cardiovascular death is complex and includes several potential factors, including a reduction in ischaemia, prevention of myocardial infarction, reduction in arrhythmias, and prevention or amelioration of congestive heart failure. Indeed, the extent to which any form of revascularization prevents cardiac death has been defined relatively poorly for patients who have stable coronary artery disease, with the exception of selected groups who have left main or significant left ventricular dysfunction.
In the initial Coronary Artery Surgery Study, 15 coronary artery bypass graft (CABG) surgery, vs. medical therapy, was associated with a reduction in sudden cardiac death; similar findings were identified in a subsequent meta-analysis of patients with left main coronary artery stenosis. 16 The effect of percutaneous revascularization on mortality is less clear 17, 18 because mortality rates were low in early trials, in which percutaneous transluminal coronary angioplasty (PTCA) was initially performed in patients with less extensive disease. The early randomized trials of PTCA vs. CABG surgery showed no difference in the intermediate-term mortality rate or the rate of myocardial infarction between the two revascularization strategies. 17, 18 In a recent meta-analysis of 13 trials 19 involving 7964 eligible patients, neither strategy (PTCA or CABG) was associated with higher survival at 1, 3 or 8 years, with the exception of patients with multivessel disease who were treated with CABG surgery. They had a survival advantage at both 5 and 8 years.
In patients treated with stent implantation instead of CABG surgery, there was discordance in the results, depending on the specific patient population studied (i.e. diabetic vs. non-diabetic, presence or absence of left ventricular dysfunction, and severity and extent of multivessel disease). [19] [20] [21] [22] [23] [24] The effect of bare metal stents compared with conventional balloon angioplasty alone has also been studied. [25] [26] [27] In a recent meta-analysis of 23 trials that enrolled 10 347 patients randomly assigned to PTCA or bare metal stent groups, there was no difference in mortality or myocardial infarction rate. 27 Similarly, in the randomized trials of stent placement vs. CABG surgery, there was no difference in mortality or myocardial infarction rate in the short-and intermediate-term follow-up. Recently, a comparative analysis of two large nonrandomized registries in New York, the Cardiac Surgery Reporting System and the Percutaneous Coronary Intervention Reporting System, after adjustment for risk factors, documented a survival benefit for patients with CAD who were treated surgically between 1999 and 2001, even though they were at higher risk at baseline. 28 The use of drug-eluting stents has dramatically changed interventional cardiology and decreased angiographic and clinical restenosis rates. Despite this improvement in restenosis, no data have emerged that suggest drug-eluting stents might reduce death more than either bare metal stents or CABG. There are several confounding issues in the available data. First, death is uncommon in the relatively uncomplicated cases and lesions studied in pivotal studies. Secondly, restenosis is usually not associated with death, although in a preliminary autopsy study, two of four cases with drug-eluting stents and in-stent restenosis had nonocclusive thrombi.
14 Thirdly, if very late subacute closure occurs more frequently with drug-eluting stents (the frequency of associated death was 45% in one series 9 ), the mortality rate could even be increased. However, most of the randomized trials included relatively low-risk patients, so the signal (i.e. mortality) might be difficult to discern from these studies.
Other studies of drug-eluting stents reported rates of death of 2-5% at the 12-month time point; death was most commonly reported as cardiac in nature. 29, 30 Rates of stent thrombosis were between 0.4 and 1.3%, and death from stent thrombosis occurred in 31-45% of patients. [29] [30] [31] [32] [33] A meta-analysis of multiple percutaneous coronary intervention studies before the advent of drug-eluting stents suggests that in the first 12 months following the intervention, most cardiac events are related to the target lesion but after 12 months they more often result from progression of disease elsewhere in the coronary circulation. 34 In this longer-term follow-up (mean follow-up, 2.6 + 0.6 years) of four randomized trials of patients who were treated with either sirolimus-eluting stents or bare metal stents, the mortality rate was low (3-4%), cardiac mortality was even lower (,1.5%), and death was most often due to non-cardiac causes. This dominance of non-cardiac deaths could be due to the low-risk profile of these patients, to the reduction of cardiac events from the treated culprit lesions, to the use of excellent secondary risk factor control, and to the use of concomitant medications such as aspirin, b-blockers, angiotensin-converting enzyme inhibitors, and statins. Although there were a few differences in early baseline characteristics between patients who survived and patients who died, procedural characteristics and outcome were very similar. There were no 
Limitations
Determination of the exact cause of death can be difficult. However, the narratives relating to the event were reviewed by both the clinical events committee for each trial and the principal author of this manuscript (D.R.H.). The patients enrolled in these four trials were a select group with low or moderate risk. Whether the results of this analysis are transferable to a wider group of patients and lesions or to other drug-eluting stents remains to be studied; while cardiac mortality is most often reported in the TAXUS series of trials, studies involving the use of both CYPHER and TAXUS stents do not indicate a difference in total, cardiac, or non-cardiac mortality. Given the size of the respective cohorts, for the observed difference in total mortality to reach statistical significance would have required a sample size of 4621 per group at 80% power with P , 0.05; for cardiac mortality, the observed difference in mortality would require a sample size of 211 053 per arm to achieve statistical significance at a similar power and level of significance.
The patients with death of unknown cause were assigned to cardiac mortality. This approach was taken to allow assumption of the worst-case scenario-whether these patients had a cardiac or non-cardiac cause of death cannot be determined. Because of the fairly restrictive definitions of stent thrombosis, it is likely that some of these 'unknown' cardiac deaths were, in fact, due to stent thrombosis. The analysis of specific differences in risk factors between patients who died and survivors also suffers from small numbers and post hoc analysis, with the potential for a spurious P-value.That analysis was not, however, the main thrust of this study, which had the aim of assessing the cause of death between the two groups.
The numerically greater non-cardiac deaths in the SES group occurred almost exclusively in C-SIRIUS and RAVEL, which were relatively small trials, but were not seen in the larger SIRIUS trial, suggesting that this imbalance is due to an uncontrolled confounder that was controlled for because of the larger size of the SIRIUS trial. In addition, the difference in non-cardiac deaths in the SES group became apparent only after 180 days, a time course inconsistent with an effect from an implanted drug-eluting stent. Thus, the most likely reason for the higher rate of non-cardiac deaths is the lack of homogeneity in enrolment in the smaller trials that contributed to this integrated analysis.
Conclusions
In this analysis, of 1748 patients entered into four trials, 878 received an SES and 870 a BMS, with a mean follow-up of 2.6 + 0.6 years. During follow-up, the incidence of all-cause death was low (3-4%) and was most often attributed to a non-cardiac cause. There was no significant difference in the specific cause of death (cardiac vs. non-cardiac) between patients receiving an SES and patients receiving a BMS, and no significant differences in the rates of stent thrombosis or death from stent thrombosis between the two groups of patients.
